Overview
The objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes mellitus (DM), as evidenced by increasing metabolism of adipose tissue.
Description
This research study aims to investigate possible activation of brown adipose tissue (BAT) metabolism by upper thoracic spinal cord stimulation (SCS). We believe that our multidisciplinary research team presents a unique opportunity to test whether SCS can activate BAT metabolism, as tested during a routine screening procedure for spinal cord stimulation (SCS) for pain control. Our marker for BAT activation is 18F-fluorodeoxyglucose (FDG) - positron emission tomography (PET), which has previously been used to gauge cold-evoked BAT activation, and other studies of BAT in humans. We believe this proof-of-concept study could pave the way for a new therapeutic modality for the treatment of morbid obesity, and Type 2 Diabetes Mellitus.
Eligibility
Inclusion Criteria:
- Age: 21-70 years
- Persistent neuropathic leg and back pain
- Subjects who are already planning to undergo SCS for pain
- Subjects who have not received a prior SCS trial for pain
- Subjects with a BMI of 25-45, using formula; weight (lb) / [height (in)]2 x 703
Exclusion Criteria:
- Not considering SCS for pain
- Forensic patient
- Taking beta blockers
- Weight change > 5% within last 3 months
- Habitual tobacco use
- Habitual excessive alcohol use
- Pregnancy
- Decisionally impaired adults
- Children
- Neonates
- Subjects with a BMI of <25 or >45